MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Net Debt 2011-2026 | VNRX
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.95 M | 910 K | -16.9 M | -7.84 M | -18.1 M | 4.29 M | -13.2 M | -10 M | -7.3 M | -20.1 M | -5.25 M | -1.79 M | -460 K | 313 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.95 M | -20.1 M | -6.47 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.24 B | $ 115.55 | 1.0 % | $ 35.1 B |  USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-10.6 M | $ 1.67 | -2.34 % | $ 2.22 M | USA |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 21.23 | 5.83 % | $ 1.13 B | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 24.46 | 3.25 % | $ 679 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.31 | 1.75 % | $ 493 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 169.8 | 1.23 % | $ 8.42 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 127.88 | 1.95 % | $ 20.3 B | USA |
 |
Guardant Health
GH
|
1.15 B | $ 88.91 | 1.18 % | $ 11.1 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 84.33 | 1.82 % | $ 5.69 B | USA |
 |
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.98 | -2.37 % | $ 8.76 M | USA |
 |
Medpace Holdings
MEDP
|
-360 M | $ 410.54 | 4.35 % | $ 11.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 27.47 | -0.58 % | $ 20 B |  Niderland |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
751 M | $ 9.54 | 2.03 % | $ 2.07 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.14 | -0.47 % | $ 4.92 M | USA |
 |
National Research Corporation
NRC
|
71.3 M | $ 17.23 | -0.12 % | $ 386 M | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 102.17 | -3.92 % | $ 8.43 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 263.8 | -0.43 % | $ 21.9 B | USA |
 |
Celcuity
CELC
|
-28.1 M | $ 121.03 | 6.58 % | $ 5.66 B | USA |
 |
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
187 M | $ 8.29 | 4.8 % | $ 1.06 B | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.78 | -0.21 % | $ 443 M | USA |
 |
Natera
NTRA
|
-177 M | $ 203.75 | 1.3 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 196.27 | -1.66 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
2.3 B | - | -0.91 % | $ 14.7 B | USA |
 |
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | USA |
 |
Precipio
PRPO
|
-2.19 M | $ 28.0 | 3.57 % | $ 44.9 M | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 6.1 | 3.39 % | $ 361 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 20.69 | 0.49 % | $ 223 M | China |
 |
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.56 | -0.64 % | $ 468 M | USA |